Chloe M. Orkin
Distinguished in Monkeypox

Chloe M. Orkin

London, ENG, GB 
Distinguished in Monkeypox
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Chloe Orkin practices in London, United Kingdom. Ms. Orkin is rated as a Distinguished expert by MediFind in the treatment of Monkeypox. Her top areas of expertise are HIV/AIDS, Monkeypox, Hepatitis, and Hepatitis C.

Her clinical research consists of co-authoring 195 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 16 articles in the study of Monkeypox.

Gender
Female

Locations

London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Biktarvy, Symtuza
Study Phase: Phase 3
Implementing Long-Acting Novel Antiretrovirals - the ILANA Study
Implementing Long-Acting Novel Antiretrovirals - the ILANA Study
Enrollment Status: Completed
Publish Date: July 08, 2024
Intervention Type: Other
An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.
An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.
Enrollment Status: Completed
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drugs: Paritaprevir+Ritonavir+Ombitasvir, Dasabuvir, Ribavirin, Glecaprevir+Pibrentasvir
Study Phase: Phase 3
View 2 Less Clinical Trials

195 Total Publications

Outcomes of real-world initiation of long-acting injectable cabotegravir and rilpivirine (LA-I CAB + RPV) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations.
Outcomes of real-world initiation of long-acting injectable cabotegravir and rilpivirine (LA-I CAB + RPV) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations.
Journal: HIV medicine
Published: July 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Orkin's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile